Leerink, Cantor Fitzgerald, Stifel, Oppenheimer and Baird acted as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo announces common stock and warrants offering, no amount given
- 3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts
- Lexeo Therapeutics initiated with a Buy at Guggenheim
- Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006
- Lexeo Therapeutics price target raised to $17 from $15 at Chardan